USPTO serial 99083309
TANGRAM
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- ADEJUNMOBI, AKIN T
- Law office
- TMEG LAW OFFICE 105
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TANGRAM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Anna King
Anna King Banner & Witcoff, Ltd.71 South Wacker Dr.Suite 3600Chicago, IL 60606Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation | ACTIVE | — |
| 009 | Downloadable and recorded computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; downloadable computer software using artificial intelligence for machine learning for use in the field of pharmaceuticals, medicines and drug discovery; recorded computer software using artificial intelligence for machine learning for use in the field of pharmaceuticals, medicines and drug discovery; downloadable databases in the field of pharmaceuticals, medicines and drug discovery; electronic databases recorded on computer media, for use in the field of pharmaceuticals, medicines and drug discovery; downloadable and recorded computer platform software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; downloadable and recorded computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery | ACTIVE | — |
| 040 | Custom manufacture of pharmaceutical and medical preparations; custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid | ACTIVE | — |
| 042 | Scientific research and development; pharmaceutical research and development services; scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; human genetic research; scientific and technical data analysis in the field of pharmaceuticals, medicines and drug discovery; scientific and technical data analysis in relation to pharmaceuticals and medicines; scientific and technical data analysis in relation to RNAi-based medicines; scientific and technical data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software; design, development, creation and maintenance of computational computer software platforms; design, development, creation and maintenance of computer software platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) featuring computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines, and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models; design of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and generating pharmaceutical and medical preparations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by E-THERAPEUTICS PLC
- Other trademarks owned by TANGRAM THERAPEUTICS PLC
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named TANGRAM
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 22, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jun 10, 2026 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Apr 24, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Oct 22, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Oct 22, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Oct 22, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Sep 2, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 2, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 2, 2025 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Aug 20, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Aug 20, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Aug 20, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Aug 20, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 20, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 20, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 20, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 14, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 10, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 13, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 13, 2025 | NWAP | NEW APPLICATION ENTERED | — |